ACTIV Public-Private Partnership

ACTIV Partnership Leadership Group

- Co-Chairs
  - Larry Tabak, NIH
  - William Pao, Roche

ACTIV Executive Committee

- Members
  - Gary Disbrow, BARDA
  - Mikael Dolsten, Pfizer
  - Anthony Fauci, NIH
  - Gary Gibbons, NIH
  - Peter Marks, FDA
  - Rajeev Venkayya, Takeda
  - Janet Woodcock, FDA

Preclinical Working Group
- Animal Models
- In Vitro Assays
- Mutation Tracking

Therapeutics Clinical Working Group
- Agent Prioritization
- Master Protocol

Clinical Trial Capacity Working Group
- Survey Development
- Clinical Trial Network Inventory
- Design Innovations

Vaccines Working Group
- Vaccines Clinical Trials
- Protective Immune Responses
- Vaccine-Associated Immune Enhancement
- Impact of Vaccines on Transmission
- Correlates of Protection

TRACE Working Group
- Variant emergence monitoring
- Resistance testing
- Data sharing

ACTIV Database & Inventory Effort